Results may vary depending on body type, lifestyle habits, workout routine, diet, and overall wellness condition
Rare risks associated with GLP-1 medications include: Pancreatitis , or inflammation of the pancreas Gallstones and inflammation of the gallbladder leading to biliary colic, sometimes related to rapid weight loss Kidney issues , often linked to dehydration Thyroid tumor warnings , based on animal studies rather than confirmed human cases These risks underscore the importance of medical supervision throughout your treatment
The FMS Peel Protocol combined with tranexamic acid injections over 4 sessions achieved more visible improvement than 6 years of previous attempts
This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
